Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01278810
- Locations
- 🇨🇳
Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT01276769
- Locations
- 🇨🇳
Cancer institute &Hospital，Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT01268943
- Locations
- 🇨🇳
radiation department, Cancer Hospital, CAMS, Beijing, Beijing, China
The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 84
- Registration Number
- NCT01187238
- Locations
- 🇨🇳
Zhejiang province cancer hospital, Hangzhou, Zhejiang, China
🇨🇳Cancer hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Cancer hospital, Chinese Academy of Medical Sciences, Beijing, China
Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01180166
- Locations
- 🇨🇳
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- Radiation: 3D-CRT based Involved Field Radiotherapy
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT01156259
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: TPDrug: EC-T
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 320
- Registration Number
- NCT01150513
- Locations
- 🇨🇳
Cancer Institute & Hospital Chinese Academy of Medical Sciences, Beijing, China
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
- Conditions
- Locally Advanced Malignant Neoplasm
- Interventions
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT01143974
- Locations
- 🇨🇳
Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, China
Felodipine Event Reduction Study
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2010-06-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 9800
- Registration Number
- NCT01136863
- Locations
- 🇨🇳
Fu Wai Hospital, Beijing, China
Regimens Comparison for Breast Cancers of Positive Lymph Nodes
- Conditions
- Breast Cancer
- Interventions
- Drug: Epirubicin, CTX, PaclitaxelDrug: Epirubicin, Paclitaxel
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 1000
- Registration Number
- NCT01134523
- Locations
- 🇨🇳
Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, China